Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium

被引:6
|
作者
Krzywdzinska, Agnieszka [1 ]
Pula, Bartosz [2 ]
Czyz, Anna [3 ]
Krzymieniewska, Beata [1 ]
Kiernicka-Parulska, Jolanta [4 ]
Mierzwa, Anna [4 ]
Szymczak, Donata [5 ]
Milanowska, Aneta [5 ]
Kiraga, Aleksandra [5 ]
Kwiecien, Iwona [6 ]
Zaleska, Joanna [7 ]
Jamroziak, Krzysztof [8 ]
机构
[1] Inst Hematol & Transfus Med, Lab Immunophenotyping, PL-02776 Warsaw, Poland
[2] Inst Hematol & Transfus Med, Dept Hematol, PL-02776 Warsaw, Poland
[3] Wroclaw Med Univ, Dept Hematol & Bone Marrow Transplantat, PL-50367 Wroclaw, Poland
[4] Univ Hosp Lords Transfigurat, Dept Haematol & Bone Marrow Transplantat, Flow Cytometry Lab, Haematol Clin Lab, PL-60101 Poznan, Poland
[5] Univ Hosp Wroclaw, Dept & Clin Haematol Blood Neoplasms & Bone Marro, Flow Cytometry & Cytomorphol Lab, PL-50367 Wroclaw, Poland
[6] Mil Inst Med, Dept Internal Med & Hematol, Lab Hematol & Flow Cytometry, PL-04141 Warsaw, Poland
[7] Med Univ Lublin, Dept Expt Hematooncol, PL-20059 Lublin, Poland
[8] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, PL-02097 Warsaw, Poland
关键词
multiple myeloma; minimal residual disease; flow cytometry; CONSENSUS GUIDELINES; DARATUMUMAB THERAPY; SURVIVAL OUTCOMES; MRD DETECTION; PLASMA-CELLS; SINGLE-TUBE; STANDARDIZATION; CD38;
D O I
10.3390/diagnostics11101872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Minimal residual disease (MRD) status is now considered as one of the most relevant prognostic factors in multiple myeloma (MM) while MRD negativity became an important endpoint in clinical trials. Here, we report the results of the first study evaluating the reproducibility of high-sensitivity flow cytometry MM MRD assessment in four laboratories in Poland. EuroFlow protocols for instrument setting standardization and sample preparation in MM MRD assessment were implemented in each laboratory. In the inter-laboratory reproducibility study, 12 bone marrow samples from MM patients were distributed and processed in participant laboratories. In the inter-operator concordance study, 13 raw data files from MM MRD measurements were analyzed by five independent operators. The inter-laboratory study showed high 95% overall concordance of results among laboratories. In the inter-operator study, 89% of MRD results reported were concordant, and the highest immunophenotype interpretation differences with regard to expression of CD27, CD45, CD81 were noticed. We confirmed the applicability and feasibility of the EuroFlow protocol as a highly sensitive method of MRD evaluation in MM. Results of our inter-center comparison study demonstrate that the standardization of MM MRD assessment protocols is highly desirable to improve quality and comparability of results within and between different clinical trials.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Multiple myeloma, immunotherapy and minimal residual disease
    Kusenda, J.
    Kovarikova, A.
    NEOPLASMA, 2016, 63 (05) : 651 - 658
  • [22] Minimal residual disease monitoring in multiple myeloma
    Davies, FE
    Rawstron, RC
    Owen, RG
    Morgan, GJ
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) : 197 - 222
  • [23] Standardisation of minimal residual disease in multiple myeloma
    Innao, V.
    Allegra, A.
    Russo, S.
    Gerace, D.
    Vaddinelli, D.
    Alonci, A.
    Allegra, A. G.
    Musolino, C.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [24] Prognostic value of minimal residual disease response assessment in multiple myeloma
    Takamatsu, Hiroyuki
    ANNALS OF ONCOLOGY, 2015, 26 : 25 - 25
  • [25] Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
    Maiolino, Angelo
    Da Costa, Elaine Sobral
    Orfao, Alberto
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [26] Clinical relevance of Minimal residual Disease assessment by NGS in Multiple Myeloma
    Martinez-Lopez, Joaquin
    Wong, Sandy
    Shah, Nina
    Bahri, Natasha
    Zhou, Kali
    Martin, Thomas
    Wolf, Jeffrey
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E179 - E180
  • [27] Post-transplant minimal residual disease assessment in Multiple myeloma
    Mookerjee, Anjali
    Dahiya, Meetu
    Gupta, Ritu
    Kumar, Rakesh
    Sharma, Atul
    Luthra, Kalpana
    Sharma, Alpana
    Kaur, Gurvinder
    Saxena, Renu
    Pandey, Ravindra Mohan
    Sharma, Om Dutt
    Sahoo, Ranjit
    Kumar, Lalit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E180 - E180
  • [28] The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
    Paiva, Bruno
    Chandia, Mauricio
    Puig, Noemi
    Vidriales, Maria-Belen
    Perez, Jose J.
    Lopez-Corral, Lucia
    Ocio, Enrique M.
    Garcia-Sanz, Ramon
    Gutierrez, Norma C.
    Jimenez-Ubieto, Ana
    Lahuerta, Juan-Jose
    Mateos, Maria-Victoria
    San Miguel, Jesus F.
    HAEMATOLOGICA, 2015, 100 (02) : E53 - E55
  • [29] The role of CD44 in the assessment of minimal residual disease of multiple myeloma by flow cytometry
    Zuo, Xiaojia
    Feng, Jinyi
    Ye, Lilin
    Xing, Miao
    Deng, Zhikui
    Gu, Xuefeng
    Liu, Dingsheng
    JOURNAL OF HEMATOPATHOLOGY, 2021, 14 (04) : 299 - 307
  • [30] The role of CD44 in the assessment of minimal residual disease of multiple myeloma by flow cytometry
    Xiaojia Zuo
    Jinyi Feng
    Lilin Ye
    Miao Xing
    Zhikui Deng
    Xuefeng Gu
    Dingsheng Liu
    Journal of Hematopathology, 2021, 14 : 299 - 307